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Abstract
Background Acellular dermal matrices present a new alterna-
tive to supporting expanders and implants for breast recon-
struction in breast cancer patients following mastectomy.
However, some studies have suggested that acellular dermal
matrix may increase the complication rates in certain clinical
settings. DermACELL acellular dermal matrix offers ad-
vanced processing in order to attempt to decrease bio-
intolerance and complications.
Methods Ten consecutive patients that presented for
breast reconstruction and were candidates for tissue ex-
panders underwent the procedure with the use of an
acellular dermal matrix. The patients underwent postop-
erative expansion/adjuvant cancer therapy, then tissue
expander exchange for permanent silicone breast prosthe-
ses. Patients were followed through the postoperative
course to assess complication outcomes. Histologic eval-
uation of host integration into the dermal matrix was also
assessed.
Results Of the ten patients, eight completed reconstruc-
tion while two patients failed reconstruction. The fail-
ures were related to chronic seromas and infection.
Histology analysis confirms rapid integration of mesen-
chymal cells into the matrix compared to other acellular
dermal matrices.
Conclusions Based on our observations, DermACELL is an
appropriate adjunct to reconstruction with expanders. Histo-
logical analysis of vascularization and recellularization sup-
port the ready incorporation of DermACELL into host tissue.
Level of Evidence: Level IV, therapeutic study.
Keywords Breast . Acellular dermalmatrix . Two-stage
reconstruction . Tissue expanders
Introduction
Following mastectomy, tissue expander reconstruction is
one of the most common methods for breast reconstruc-
tion [1]. The use of acellular dermal matrices (ADMs) has
been popularized in the use of tissue expander reconstruc-
tion. This biologic matrix provides support in the lower
pole of the breast and helps define the lower pole and
inframammary fold. It also speeds the rate of expansion
by reducing tension of the mastectomy skin and allows
higher initial fill volumes. These two attributes help to
decrease the overall length of the reconstruction process.
Most recently, it has been suggested that ADMs help
prevent capsular contracture, a common long-term problem
with implants in the reconstructed breast [2–4]. Although
our institutional experience has been promising, other
studies have suggested mixed, although generally positive,
findings concerning the use of ADMs [3, 5]. Since clinical
procedures are generally standardized, this suggests that
the relative ability of the various ADMs to incorporate
into soft tissues may relate to the manufacturing or pro-
cessing of the particular material. Incorporation confers
biocompatibility, which ultimately creates symmetry within
the host. Bio-incompatibility due to lack of incorporation
may cause seroma, infection, and reconstructive failure [6].
The reconstructive process can be difficult enough for the
patient without adding further cosmetic complications.
Structural support of the breast is necessary to provide
the ideal breast shape and implant position. ADMs have
been recognized as being beneficial by serving as a sup-
plemental graft in breast reconstruction cases. They can
supplement muscle coverage, shape the breast and
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inframammary fold, and possibly reduce the number of
surgeries patients need to undergo. This technique utilized
in breast reconstruction brings with it many benefits [7].
Acellular dermal matrices are composed of the dermal
layer and extracellular matrix of thin layers of donated
skin that have had the epidermal layer removed. Donor
cellular material including major histocompatibility com-
plex (MHC) proteins are removed in a series of further
treatments to theoretically minimize immunological re-
sponse in ADM recipients [8]. The ability of ADMs to
promote significant revascularization and cellular infiltra-
tion make them an encouraging option for an array of
tissue regeneration applications, including wound
healing, soft tissue reconstruction, and augmentation
[9–27].
A recently developed human ADM produced by an anionic
detergent and endonuclease-based decellularization process
[28] is a product trade-named DermACELL® (LifeNet
Health, Virginia Beach, VA, USA). Unique features of this
allograft include removal of at least 97 % DNA, an indication
of complete decellularization and potentially reduced immu-
nogenicity, terminally sterilization to a Sterility Assurance
Level of 10−6, and being provided at room temperature and
ready to use directly out of the package.
Here, we examine the post-mastectomy outcome of a two-
stage breast reconstruction using this new human acellular




This prospective, consecutive cohort series included 10
female patients ranging in age from 33 to 59 years old
who underwent mastectomies and presented to have
breast reconstructions with the use of DermACELL. Of
the 10 patients, eight had bilateral mastectomies and
two had unilateral mastectomies, for a total of 18
breasts. One patient elected to have a prophylactic bi-
lateral mastectomy after testing positive for the BRCA-1
gene. Two patients underwent unilateral mastectomies,
one of whom had previously undergone a unilateral
mastectomy and reconstruction of the contralateral
breast. The remaining patients each presented with
breast cancer unilaterally and elected to have a mastec-
tomy of the affected breast, as well as prophylactic
mastectomy of the contralateral breast. Of the 10 pa-
tients, two were smokers (Table 1). Two patients re-
quired neo-adjuvant chemotherapy, one required adju-
vant chemotherapy, one additional patient required both
neo-adjuvant and adjuvant chemotherapy, and two re-
quired radiation.
Breast reconstruction was performed in two stages. In the
first stage, DermACELL and expanders were used. Following
tissue expansion, patients advanced to the second stage of the
procedure of immediate reconstruction for final placement of
silicone implants.
Clinical procedures
Each reconstruction included placement of Mentor CPX3 tall
height contour profile implants (Mentor Worldwide LLC,
Santa Barbara, CA, USA) for tissue expansion and 16×
6 cm2 DermACELL patches, with one patient’s DermACELL
patch tailored down to 12×6 cm2. All expanders were placed
with an initial volume of 100 cc intraoperatively using sterile
saline. The pectoris muscle was elevated and the
DermACELLwas sutured to the inferior portion of the muscle
and to the inframammary fold to serve as a sling. A drain was
placed in the breast pocket and in the subcutaneous pocket
between the mastectomy skin and the DermACELL. Two
weeks postoperative expansion began and continued between
7 and 46 weeks (average 8 weeks) until the desired volume.
Drains were removed between 6 and 21 days postoperatively
(average 15 days) depending on their output.
Histological analysis
Biopsy samples were taken from the patients and sent in
formalin to Dominion Pathology Laboratories (Norfolk, VA,
USA) for sectioning and staining. Hematoxylin and eosin
(H&E) staining was undertaken to assess cellularity and general
ultrastructure. Additionally, immunohistochemical staining for
the endothelial cell marker CD34 (CD34) was used to assess
vascularity and Verhoef-Von Gieson (VVG) staining was per-
formed to assess elastic fibers and general ultrastructure. His-
tological assessments were determined by dermatopathologists
Kevagn Fair, MD (Dominion Pathology) and Antoinette Hood,
MD (Eastern Virginia Medical School, Norfolk, VA, USA).
Results
Patient overview and results
Eight (15 breasts) of the 10 breast reconstruction procedures
were successfully completed and only minor complications
were reported in two patients (Table 2). Major complications
were seen in the two patients with failed breast reconstructions
due to smoking and infection. Patient outcomes were as
follows (Table 2): four breasts developed seromas, there were
two surgical site infections, four experienced delayed healing,
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and three had flap necrosis. Of particular note, there was no
observation of hematomas or red breast syndrome in any
patient. Over half of the observed complications were limited
to a single patient, limiting the complicative profile and asso-
ciating patient comorbidities as the major contributor. It ap-
pears that a history of smoking caused mastectomy skin
necrosis and a port-a-cath wound infection contributed to the
failed reconstruction. This patient developed seromas of both
breasts, a purulent right breast infection, and mastectomy flap
necrosis of both breasts. This patient also had postoperative
radiation and significant skin necrosis, apparently due to the
radiation. She also eventually developedmetastatic cancer and
did not return to undergo reconstruction. The other patient
who failed reconstruction developed a seroma, surgical site
infection, flap necrosis, and experienced delayed healing of
the left breast. These complications were most likely the result
of the patient continuing to smoke throughout her postopera-
tive recovery. The expanders were removed and the recon-
struction was aborted.
Six patients that completed reconstruction did not experi-
ence any complications. Patient 2 (Fig. 1) was one of these six
patients that had a successful reconstruction with no infec-
tions, seromas, or other possible complications. She was
43 years old, had neoadjuvant chemotherapy for a left locally
advanced breast cancer, and was advised to have a mastecto-
my. The patient also requested a contralateral prophylactic
mastectomy with immediate reconstruction of both breasts.
From histological analysis (Fig. 2), it is evident that the
DermACELL had incorporated into the host tissue and
allowed for revascularization. The tissue was infiltrated with
fibroblasts and blood vessels.
Another notable completed reconstruction was performed
on patient 5 (Fig. 3). She was 33 years old, had a strong family
history of breast cancer, and therefore decided to be tested for
the BRCA-1 gene mutation. The patient tested positive for the
mutation and elected to undergo prophylactic mastectomy of
both breasts with immediate breast reconstruction. A seroma
developed on the left breast between the skin and the
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1 50 Adj. No Bilateral 46 400 cc No 400 cc
2 43 No No Bilateral 24 400 cc No 600 cc
3 52 No No Bilateral 9 380 cc No 425 cc
4 43 Neo-adj./Adj. Yes Bilateral N/A X Yes X
5 33 No No Bilateral 7 550 cc No 500 cc
6 56 Neo-adj. No Bilateral N/A X Yes X
7 59 No No Bilateral 20 700 cc No 700 cc
8 45 Neo-adj. Yes Unilateral (R) 41 600 cc No Flapa
9 48 No No Unilateral (R) 43 220 cc No 175 cc
10 33 No No Bilateral 20 500 cc No 555 cc
a Planned autologous reconstruction in a delayed fashion
Table 2 Patient outcomes












1 0/2 0/2 0/2 0/2 0/2 0/2 2/2 0/2
2 0/2 0/2 0/2 0/2 0/2 0/2 2/2 0/2
3 0/2 0/2 0/2 0/2 0/2 0/2 2/2 0/2
4 2/2 0/2 1/2 0/2 2/2 2/2 0/2 2/2
5 1/2 0/2 0/2 0/2 0/2 0/2 2/2 0/2
6 1/2 0/2 1/2 0/2 1/2 1/2 0/2 2/2
7 0/2 0/2 0/2 0/2 0/2 0/2 2/2 0/2
8 0/1 0/1 0/1 0/1 0/1 0/1 1/1 0/1
9 0/1 0/1 0/1 0/1 1/1 0/1 1/1 0/1
10 0/2 0/2 0/2 0/2 0/2 0/2 2/2 0/2
Total 4/18 0/18 2/18 0/18 4/18 3/18 15/18 4/18
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DermACELL on day 10. A drain was placed between the skin
and DermACELL, and was then removed 1 week later. The
patient had expansion for about 7 weeks and then returned for
tissue expander removal and placement of the permanent
implants. At this time, the DermACELL was found to be
incorporated into the surrounding tissues.
Patient 10, one of the eight patients with completed recon-
struction, was a 33-year old who originally presented for
breast augmentation (Fig. 4). During her preoperative screen-
ing, she was found to have left breast cancer and was
counseled to undergo mastectomy. The patient agreed to have
left breast mastectomy and also opted to have prophylactic
right breast mastectomy followed by immediate breast recon-
struction. After expansion continued to the desired volume,
the tissue expander implants were removed at 20 weeks and
replaced with permanent silicone breast implants. During
placement of the permanent implants, it was noted that the
DermACELL matrix had incorporated into the surrounding
tissue and showed signs of granulation budding (Fig. 5).
Histological analysis
Histology analysis confirms the incorporation of the
DermACELL matrix into the surrounding tissue, aiding in
reconstruction. Observations for all biopsy samples included
presence of fibroblasts, intact ultrastructure including elastin,
and vasculature (Figs. 6, 7, and 8). Rarely, a foreign body
response was observed and was noticeable at the same posi-
tion as polarizable material. The foreign body response was
consistent with suture material, as evidenced by the regular
pattern and minimum associated inflammation. Pseudo-
capsule formation was generally seen on the side of the
implant facing the expander, which occurred as a benign
response to the expander material. The opposite interface
between the implant and the host tissue exhibited some tissue
integration and minimal inflammation, which was consistent
with normal healing. The implant material looked more orga-
nized with less vasculature and fewer living cells compared to
host tissue. These findings are consistent for a stable material
Fig. 1 a, b Patient 2 preoperative
before undergoing bilateral
mastectomy with immediate
reconstruction. c, d Patient 2
postoperative 7 months after
placement of permanent implant
Fig. 2 a, b H&E stain of
DermACELL sample taken from
patient 2’s left breast at 7 months
postoperative. Viewed under
×100. The upper arrows identify
blood vessels while the lower
arrows identify fibroblasts
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being slowly incorporated and remodeled after a few weeks to
a few months after surgery when biopsy samples were taken.
Discussion
Overall, excellent results were noted with DermACELL in
two-stage breast reconstruction. This consecutive cohort se-
ries did not exclude challenging patients. Most complications
were isolated to two compromised patients. The most compli-
cations were observed in the patient who was an occasional
smoker. This was not unexpected as Anthony et al. [29] noted
a trend towards significance in their study on the incidence of
complications in breast reconstruction using acellular dermal
matrices. Padubidri et al. [30] demonstrated a significant
complication rate for smokers in their retrospective study of
hundreds of breast reconstruction patients. Other studies have
also noted an increased incidence of complications of
patients who smoke after post-mastectomy breast recon-
structions [31, 32].
In addition to the immediate advantages of providing struc-
tural support, the ultimate goal of using ADM’s is to enable
integration of the matrix into the host tissue. This integration
can be quantified by examining the revascularization
and recellularization of the ADM. The two blinded
dermatopathologists, who assessed DermACELL sam-
ples, identified numbers of blood vessels and fibroblasts
that support incorporation into the host cell.
A similar case series [33] was recently published where
DermACELLwas used for two-stage breast reconstructions in
10 breast cancer patients. After excluding one patient for
Fig. 3 a Patient 5 preoperative
before undergoing bilateral
mastectomy with immediate
reconstruction. b Patient 5
postoperative 1 month after
exchange of tissue expander for
implant
Fig. 4 a Patient 10 preoperative
before undergoing bilateral
mastectomy with immediate
reconstruction. b Patient 10
postoperative 7 months after
mastectomy and placement of
tissue expanders and
DermACELL
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tobacco use, the author found comparable results with 14 out
of 17 breasts successfully reconstructed to the second stage
implant sequence. There were few complications reported,
including the noteworthy absence of red breast syndrome in
all patients, and most postoperative complications occurred in
a patient who relapsed into tobacco use. Histological analysis
of biopsy samples taken of the ADM from eight patients
indicated incorporation with minimal inflammation and nor-
mal healing, consistent with our findings.
Another study [34] using in vivo rat models compared
several different ADM’s, including DermACELL. The results
of the study of Capito et al. support our findings. At day 7
postoperative, the DermACELL matrices had nearly twice the
number of blood vessels as the next highest ADM. In regards
to recellularization, it was found that DermACELL had the
statistically significant highest amount of cell density at days
7, 14, and 21 postoperative as well as the greatest amount of
cell infiltration.
The success reported here with DermACELL may be due
to the processing and sterility of the material. The process
involves the use of a solution of non-denaturing anionic
detergent (N-Laurol sarcosinate), recombinant endonuclease
(Benzonase® (Merck KGaA, Darmstadt, Germany), and antibi-
otics (Polymixin B, Vancomycin, and Lincomycin), resulting in
a material that exhibits at least 97 % nucleic acid removal, while
maintaining biomechanical strength. DermACELL allografts are
preserved in glycerol, stored at room temperature, and are ready
to use without needing to be rehydrated [35]. The allografts are
terminally sterilized at ultra-low temperatures to achieve a 10−6
sterility assurance level [35, 36]. The temperature of irradiation
has proved to be important because sterilizing grafts at very low
temperatures minimizes free radicals and eventual tissue damage
[37, 38]. In addition to the temperature at which irradiation
occurs, the solutions used to clean the human tissue can deter-
mine the quality of the allograft. When harsh chemicals such as
acetone, sodium hydroxide, and hydrogen peroxide are used,
they can greatly damage the soft tissue [39]. Many factors are
involved in the processing of a human tissue allograft with a
sterility assurance level of 10−6. An allograft with a sterility
assurance level of 10−6 is equivalent to the level of sterility
provided with implantable medical devices, and the use of such
sterile allografts could result in a lower rate of infection than
Fig. 5 Patient 10, 5 months after expansion of the DermACELL, the
matrix is incorporated into the surrounding tissue and show signs of
granulation
Fig. 6 Hematoxylin and eosin staining of biopsy from patient #1 follow-
ing 16 weeks in situ placement of acellular dermal matrix. Note the intact
ultrastructure and also evidence of cellular in-growth as apparent fibro-
blasts (arrows) at ×10 magnification
Fig. 7 CD34 staining of biopsy from patient #1 following 16 weeks in
situ placement of acellular dermal matrix. Evidence of robust vasculari-
zation is noted by reddish-brown stains apparently associated with blood
vessels (arrows) at ×10 magnification
Fig. 8 Verhoef-VanGeisen staining of biopsy from patient #1 following
16 weeks in situ placement of acellular dermal matrix. Note abundance of
elastin (arrows) in this ×10 magnification
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when using autografts obtained from a second procedural site
[40, 41]. By using low doses of gamma irradiation at very low
temperatures, this process is able to ensure a high degree of
safety without compromising biological and biomechanical
properties [42–46]. The decellularization process used to prepare
DermACELL is designed to remove cellular elements while
retaining matrix structure, theoretically yielding a material with
reduced antigenicity, increased biocompatibility, and subse-
quently reduced complications.
AlloDerm® (LifeCell Corporation, Bridgewater, NJ,
USA), a decellularized human dermal matrix, is aseptically
processed and freeze-dried. It is treated with a buffered salt
solution to separate and eliminate the epidermis, then washed
with a series of mild non-denaturing detergent solutions to
solubilize and eliminate all cells [47]. AlloDerm undergoes a
sterilization process that includes electron beam irradiation,
which provides for a sterility assurance level of 10−3.
FlexHD® (Musculoskeletal Transplant Foundation, Edison,
New Jersey, USA) is human allograft skin that is minimally
processed to remove epidermal and dermal cells, a process
that maintains the integrity of the matrix. It is packaged in an
ethanol solution and must be soaked in a sterile solution
before implantation. The allograft tissue complies with the
requirements of United States Pharmacopeia (USP) <71>
Sterility tests but is not terminally sterilized, and thus claims
no level of sterility assurance [48].
While all of these products are acellular dermal matrices,
there are many differences between the three, including the
degree of sterilization. DermACELL maintains a sterility assur-
ance level of 10−6, which assures that no more than one in a
million implants could potentially be infected with microorgan-
isms. In comparison, AlloDerm is only aseptic with a sterility
assurance level of 10−3 and, in theory, about one in one thousand
implants could potentially be infected. FlexHD is not terminally
sterilized, butmeets the requirements of USP<71> Sterility tests.
The same sterility standards are not followed by all orga-
nizations that supply bone and tissue allografts. Since there is
no standard definition of sterile, there can be clinical concern
and confusion regarding infection [49]. Contaminated allo-
grafts can cause significant complications or even death in
patients who receive the infected tissue [50]. In addition to
compromising the health of patients, surgical site infections
due to contaminated allografts can place a notable financial
burden on patients, hospitals, and health care providers. As
determined by the Centers for Medicare and Medicaid Ser-
vices (CMS), surgical site infections are considered to be
preventable complications and hospitals will not be reim-
bursed for the care of patients suffering from such complica-
tions [51]. In 2005, a study performed in Pennsylvania report-
ed that the average charge for patients that developed a hos-
pital infection ($173,206) was about four times as high as the
charge for patients with the same diagnosis who did not
contract an infection ($44,367) [52]. Therefore, allograft-
associated infections place additional financial burden on
patients and have a significant economic impact on hospitals.
Rigorous screening, in combination with stringent aseptic
tissue processing followed by terminal sterilization, can help
eliminate allograft-associated infections [48].
Fig. 9 Six-week postoperative biopsy for DermACELL. The upper
arrow identifies a fibroblast and the lower arrow identifies a blood vessel
Fig. 10 Postoperative biopsy for AlloDerm. The arrow on the left
identifies a blood vessel and the arrow on the right identifies a fibroblast
Fig. 11 Postoperative biopsy for FlexHD. The upper arrow identifies a
hematoma and the lower arrow identifies a fibroblast
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Decellularization of human allograft tissue performed dur-
ing tissue processing results in a material devoid of immuno-
genic components, theoretically allowing for improved graft
biocompatibility, incorporation, and healing. A key measure
of the effectiveness of decellularization is removal of DNA.
The decellularization process used in the treatment of
DermACELL results in at least a 97 % reduction in the
DNA content of the tissue, reduced, in one analysis, to ap-
proximately 15.97 ng/mg dry weight. The residual DNAvalue
for AlloDerm is much higher at 272.8 ng/mg dry weight [36].
The presence of erythema of mastectomy skin flaps fol-
lowing matrix implant, also known as “red breast syndrome,”
has been reported when using either human or xenograft
matrices [20, 53, 54]. While not fully understood, it is sug-
gested that this may be an inflammatory response to the
implanted matrix or preservatives [20, 53]. It is of special
interest to note that there were no cases of red breast syndrome
in this case series using DermACELL.While no generalizable
conclusions can be reached from this small patient population,
the processing of DermACELL ADM resulting in significant
reduction in DNA and cellular content may result in the
absence of erythema.
To compare the effectiveness of different acellular dermal
matrices, histological analysis was performed on biopsies
taken as part of this cohort and from additional two-stage
breast reconstruction patients, also treated by this study au-
thor. One patient had received AlloDerm, while FlexHD was
used in the second patient. At 6 weeks postoperative,
DermACELL tissue was infiltrated with fibroblasts and blood
vessels (Fig. 9). The revascularization of the DermACELL
tissue indicates that incorporation has occurred. In compari-
son, the AlloDerm tissue biopsy (Fig. 10) did not have nearly
as many blood vessels and fibroblasts as the DermACELL
tissue. A postoperative biopsy of FlexHD also showed a lack
of revascularization (Fig. 11) in our study at the same time
point. Further studies are needed for direct comparisons be-
tween DermACELL and other ADMs.
It is important for successful breast reconstructions utiliz-
ing acellular dermal matrices to facilitate the incorporation of
the host tissue into the allograft material. Acellular dermal
matrices are able to support larger and faster tissue expansion,
reduce capsular contracture, and decrease the rate of revision
[55–58]. The ability of DermACELL to incorporate into host
tissue with good revascularization and recellularization could
provide for quicker breast reconstructions with fewer
complications.
Conclusion
DermACELL appears to be an appropriate adjunct to recon-
struction with expanders. Overall, patients that experienced
the most complications postoperatively were those with
unhealthy lifestyle behaviors, most notably smoking. The
results of our case series suggest that DermACELL is at least
comparable to other ADMs, within the limitations of the small
cohort size. DermACELL’s advanced processing may also
reduce complications that lead to reconstruction failure. His-
tologic analysis reveals early integration at 6 weeks post-
implantation.
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